Skip to content
Clinical Trials for Alzheimer's Disease

Orlando, Florida

Alzheimer's disease clinical trials in Orlando, FL

19 Alzheimer's disease studies are recruiting participants at sites in Orlando as of November 16, 2026, according to ClinicalTrials.gov. Clinical Trials for Alzheimer's Disease can help you understand your options and connect with a study team.

Call (888) 927-5895
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Orlando at a glance

  • 19 studies are recruiting at a site in Orlando.
  • By phase: Phase 1 (1), Phase 1/2 (2), Phase 2 (6), Phase 2/3 (1), Phase 3 (6), No phase (1), Observational (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (18), university, hospital or other (1).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Orlando

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    • Phase 3
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Charter Research - Winter Park/Orlando · Conquest Research - Lake Nona
    Registry record
    NCT07177352 · updated
  2. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study sites
    Combined Research Orlando Phase I-IV LLC · Nova Psychiatry
    Registry record
    NCT05980949 · updated
  3. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  4. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Combined Research Orlando (CRO)
    Registry record
    NCT07011732 · updated
  5. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Sanofi
    Study site
    K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008
    Registry record
    NCT07688213 · updated
  6. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

    • Phase 3
    • Ages 55 to 80
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Charter Research - Winter Park/Orlando · Conquest Research - Lake Nona
    Registry record
    NCT07717411 · updated
  7. ACP-204 in Adults With Alzheimer's Disease Psychosis

    • Phase 2/3
    • Ages 55 to 95
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study site
    Combined Research Orlando Phase I IV
    Registry record
    NCT06159673 · updated
  8. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Charter Research - Orlando
    Registry record
    NCT07589595 · updated
  9. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Charter Research
    Registry record
    NCT06651567 · updated
  10. An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

    • Phase 1
    • Ages 30 to 80
    • All sexes
    Sponsor
    Voyager Therapeutics
    Study site
    AdventHealth Orlando
    Registry record
    NCT07764146 · updated
  11. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Charter Research - Orlando · Headlands Research Orlando
    Registry record
    NCT07602582 · updated
  12. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study sites
    Charter Research Orlando · Combined Research Orlando Phase I-IV LLC · Nova Psychiatry
    Registry record
    NCT06585787 · updated
  13. A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

    • Phase 2
    • Ages 50 to 85
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Charter Research - Orlando ( Site 1051)
    Registry record
    NCT07033494 · updated
  14. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

    • Phase 2
    • Ages 55 to 80
    • All sexes
    Sponsor
    Lighthouse Pharmaceuticals, Inc.
    Study site
    Conquest Research - Lake Nona
    Registry record
    NCT06847321 · updated
  15. Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

    • Phase 1/2
    • Ages 40 to 85
    • All sexes
    Sponsor
    NKGen Biotech, Inc.
    Study site
    AdventHealth Research Institute
    Registry record
    NCT06189963 · updated
  16. A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

    • Phase 1/2
    • Ages 35 to 85
    • All sexes
    Sponsor
    AC Immune SA
    Study site
    Charter Research, LLC
    Registry record
    NCT05462106 · updated
  17. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

    • Observational
    • Ages 60 to 90
    • All sexes
    Sponsor
    GAP Innovations, PBC
    Study site
    Charter Research
    Registry record
    NCT06584357 · updated
  18. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

    • No phase
    • Ages 50 to 85
    • All sexes
    Sponsor
    InSightec
    Study site
    Advent Health
    Registry record
    NCT03671889 · updated
  19. University of Central Florida CereBank

    • Observational
    • Ages 18 and older
    • Female participants
    Sponsor
    University of Central Florida
    Study site
    University of Central Florida
    Registry record
    NCT06876857 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Orlando, FL on ClinicalTrials.gov.

Ask about studies near Orlando

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5895

or send a short form

How should we reach you?

Call